Remove Pharma Companies Remove Production Remove Vaccination
article thumbnail

Covid vaccine profits and the strain on supply channels

World of DTC Marketing

SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others. So far the winners are Pfizer and Moderna.

Vaccine 266
article thumbnail

‘Right shoring’ API production in Europe

Pharmaceutical Technology

Despite having large biopharmaceutical companies on home ground, the UK and France experienced major shortages and supply chain issues. Only 25% of API production for generic drugs took place in Europe in 2020, according to a November 2022 Medicines for Europe report. For innovative medicines, this share was 77%.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

COVID 19 vaccine means big money and greed

World of DTC Marketing

QUICK READ : Pharma had a chance to earn some goodwill with a very skeptical public but it’s become obvious that the rush to develop a vaccine is about profit, executive stock, and Wall Street despite potential huge investments from the government. Moderna, a 10-year-old vaccine developer based in Cambridge, Mass.,

Vaccine 181
article thumbnail

mRNA Vaccine Manufacturing Comes to Africa

BioSpace

The COVID-19 pandemic highlighted a need for local production of vaccines. Now, German pharma company BioNTech has said it will start manufacturing vaccines in Africa.

article thumbnail

Brazil: untapped market for big pharma manufacturing

Pharmaceutical Technology

SUS provides full, free and universal access to healthcare for the country's entire population (215 million), which spends around 10% of its gross domestic product (GDP) on healthcare. Only a limited number of international pharma companies, however, operate manufacturing sites in the country.

article thumbnail

HCP’s use of social media: the good and the not so good

World of DTC Marketing

86% of diagnostic device companies, 65% of pharma marketers, and over half of biotechs use social as a critical part of their marketing mix to reach HCPs. Doximity was flagged for having anti-vaccine information. HCPs don’t necessarily want pharma trying to sell products via social media.

Nurses 294
article thumbnail

Cancer vaccines: providing the edge in oncology

pharmaphorum

In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. The oncology segment has been recognised as one of the most productive areas for pharmaceutical companies to focus their R&D investment.

Vaccine 134